Widespread ocular use of topical chloramphenicol: Is there justifiable concern regarding idiosyncratic aplastic anaemia?

British Journal of Ophthalmology

Volumn 80, Issue 2, 1996, Pages 182-184

  McGhee, Charles N J ^a,b   Anastas, Constantine N ^a  

^a SUNDERLAND EYE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL;

APLASTIC ANEMIA; BONE MARROW TOXICITY; DRUG HYPERSENSITIVITY; DRUG USE; EYE INFECTION; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICOLEGAL ASPECT; PRIORITY JOURNAL; RASH; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION;

EID: 0030041212     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.80.2.182     Document Type: Short Survey

References (33)

1. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? [Editorial]. BMJ 1995; 310: 1217-8.
2. Kirkness CM, Seal DV, Hay J. Topical chloramphenicol: use or abuse? Eye 1995; 9 (4): vii-viii.
3. Buckley RJK, Kirkness CM, Kanski JJ, Ridgway AEA, Tullo AB, Watson PG. Is it time to stop using chloramphenicol on the eye? Safe in patients with no history of blood dyscrasias [Letter]. BMJ 1995; 311: 450.
4. Hall AV, Das SS, Tabaqchali S. Is it time to stop using chloramphenicol on the eye? Risk is low in short courses [Letter]. BMJ 1995; 311: 450-1.
5. Gordon-Smith EC, Marsh JCW, Geary CG. Is it time to stop using chloramphenicol on the eye? Prospective study of aplastic anaemia should give definitive answer [Letter]. BMJ 1995; 311: 451.
6. Rich ML, Ritterhoff RJ, Hoffman RJ. A fatal case of aplastic anaemia following chloramphenicol (chloromycetin) therapy. Ann Intern Med 1950; 33: 1459-67.
7. Flegg P, Cheong I, Welsby PD. Chloramphenicol: are concerns about aplastic anaemia justified? Drug Safety 1992; 7: 167-9.
8. Best WR. Chloramphenicol-associated blood dyscrasias. JAMA 1967; 201: 181-8.
9. Buckley SA. Survey of patients taking topical medication at their first presentation to eye casualty. BMJ 1990; 300: 1497-8.
10. Smilack JD, Wilson WR, Cockerill FR. Tetracyclines, chloramphenicol, erythromycin, clindamycin and metronidazole. Mayo Clin Proc 1991; 66: 1270-80.
11. Mauger TF. Antimicrobials. In: Mauger TF, Craig EL, eds. Havener's ocular pharmacology. 6th ed. St Louis: Mosby, 1994: 274-8.
12. Hanna C, Massey JY, Hendrickson RO, Williamson J, Jones EM, Wilson P. Ocular penetration of chloramphenicol. Arch Ophthalmol 1978; 96: 1258-61.
13. Lafarge-Frayssinet C, Robbana-Barnat S, Frayssinet C, Toucas L, Decloitre F. Cytotoxicity and DNA damaging potency of chloramphenicol and six metabolites: a new evaluation in human lymphocytes and Raji cells. Mutation Res 1994; 320: 207-15.
14. Aragones JV, Eriksen SP. Stable chloramphenicol solution for ocular infections. Am J Ophthalmol 1968; 66: 104-6.
15. Sinclair NM, Leigh DA. A comparison of fusidic acid viscous eye drops and chloramphenicol eye ointment in acute conjunctivitis. Therapeutic Res 1988; 44: 468-74.
16. Beasley H, Boltralik JJ, Baldwin HA. Chloramphenicol in aqueous humor after topical application. Arch Ophthalmol 1975; 93: 184-5.
17. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993.
18. Leeming JP, Diamond JP, Trigg R, White L, Hoh HD, Easty D. Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora. Br J Ophthalmol 1994; 78: 546-8.
19. Power WJ, Collum LM, Easty DL, Bloom PA, Laidlaw DA, Libert J, et al. Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol. Eur J Ophthalmol 1993; 3: 77-82.
20. Erslev AJ. Drug-induced blood dyscrasias: I. Aplastic anaemia. JAMA 1964; 188: 159-60.
21. Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. Statewide study of chloramphenicol therapy and fatal aplastic anaemia. JAMA 1969; 208: 2045-50.
22. Trope GE, Lawrence JR, Hind VMD, Bunney J. Systemic absorption of topically applied chloramphenicol eyedrops. Br J Ophthalmol 1979; 63: 690-1.
23. Fraunfelder FT, Bagby GC, Kelly DJ. Fatal aplastic anaemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93: 356-60.
24. Abrams SM, Degnan TJ, Vinciguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. Arch Intern Med 1980; 140: 576-7.
25. Nagao T, Mauer AM. Concordance for drug-induced aplastic anaemia in identical twins. N Engl J Med 1969; 281: 7-11.
26. Faunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812-3.
27. Rosenthal RL, Blackman A. Bone-marrow hypoplasia following use of chloramphenicol eye drops. JAMA 1965; 191: 148-9.
28. Carpenter G. Chloramphenicol eye-drops and marrow aplasia. Lancet 1975; ii: 326-7.
29. Dutro MP. Chloramphenicol and aplastic anaemia. Am J Ophthalmol 1981; 92: 870-1.
30. Stevens JD, Mission GP. Ophthalmic use of chloramphenicol [Letter]. Lancet 1987; ii: 1456.
31. Mandell GL, Sande MA. Penicillins, cephalosporins, and other beta-lactam antibiotics. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, ed. The pharmacological basis of therapeutics. Vol II. 8th ed. Singapore: McGraw-Hill Book Co, 1992: 1081-5.
32. Gassner B, Wuethrich A. Pharmacokinetic and toxocological aspects of the medication of beef-type calves with an oral formulation of chloramphenicol palmitate. J Vet Pharmacol Ther 1994; 17: 279-83.
33. Page SW. Chloramphenicol. I: Hazards of use and current regulatory environment. Aust Vet J 1991; 68: 1-2.